Intellihealth Launches Evolve Mobile 3.0

Intellihealth, a leading health-tech software and clinical services company that delivers a comprehensive and clinically proven medical model for treating obesity, has introduced version 3.0 of Evolve Mobile, the patient-side mobile app companion to the Evolve software-as-a-service platform for healthcare providers.

Intellihealth’s EvolveTM is a turnkey medical obesity treatment solution that easily integrates into any practice and streamlines all aspects of care, including assessment, diagnosis, prescription and treatment. Patients’ individualized treatment plans — addressing diet, behavior and psychology, as well as pharmacotherapy when appropriate — are developed and continually refined by expert obesity clinicians based on factors such as their medical history and health risks, electronic health record information, data from wearables and connected devices, and learning center progress.

Evolve Mobile 3.0 includes two significant new features: medication monitoring, which enables patients to set up personalized reminders to take their anti-obesity medications regularly and allows both patients and providers to monitor patterns to make sure prescriptions are being followed; and Apple Health and Google Fit integration, which supports seamless access to weight, blood pressure and heart-rate data from connected devices. Together, these tools offer patients and providers a more comprehensive view of overall health and program compliance over time. The upgrade also incorporates a range of performance improvements and updates throughout the app.

“Remote medication monitoring can improve the efficacy of treatment for many chronic diseases, and obesity is no exception,” said Venky Surya, CPTO at Intellihealth. “With Evolve Mobile 3.0, care teams can better monitor their patients’ medication usage as well as a variety of critical indicators, allowing them to closely track patients’ overall health and weight-loss progress and respond quickly when individualized treatment plans need to be adjusted. This reinforces positive messaging and leads to better patient engagement in our programs.”

The new features extend the app’s existing capabilities, which include meal planning tailored to individual dietary preferences; easy food, weight and activity logging; regular virtual visits and messaging with care team members; and educational resources and other tools to support engagement.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version